“Genetic testing is really about the patient, and it is helpful to find out what is the patient’s risk” to a particular disease explained Edmund Pezalla, MD, MPH. He thinks that research in this field—prediction of an individual’s risk for a particular type of cancer such as breast or prostate or colon cancer— is currently in its early stages.
“Genomics, on the other hand is about the tumor itself. The tumor has a different genetic makeup than the patient, and it might actually have a different genetic makeup subsequent to treatment. So a tumor further down the treatment road may be different from where it started,” said Dr Pezalla.
“So genomics is important in that it specifically tells us about the tumor that the patient has and it helps us guide treatment, while genetics is about the patient and it helps us guide screening and other preventive services,” he explained.
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Early Intervention, Targeted Strategies Needed to Improve Disparities, Survival in Patients With IPF
October 17th 2024Two posters presented at the CHEST 2024 annual meeting highlighted the importance of addressing socioeconomic disparities and identifying clinical predictors to improve outcomes and survival rates among patients with idiopathic pulmonary fibrosis (IPF).
Read More